New Product Launch GOMBRICH®cabazitaxel

05/07/2023

Bioprofarma Bagó is proud to present the launch of GOMBRICH® cabazitaxel, for its Oncology Business Unit.

GOMBRICH® cabazitaxel is used for the treatment of prostate cancer that has progressed after having received other chemotherapy. It works by stopping cell growth and multiplication.

GOMBRICH® cabazitaxel is available as a concentrated solution for infusion in a single presentation consisting of one 60 mg vial and one vial of diluent.

GOMBRICH® cabazitaxel is a taxane that joins the portfolio of products indicated for prostate cancer, together with KESTAVA® abiraterone and DONATAXEL® docetaxel.

XXVI Argentine and International Congress of Clinical Oncology organized by the AAOC

November 8-10, the XXVI Argentine and International Congress of Clinical Oncology 2023 was held at La Rural, in the City of Buenos Aires, and Bioprofarma Bago was there.

Read note

26th ARGENTINE CONGRESS OF HEMATOLOGY organized by the Argentine Society of Hematology

Bioprofarma Bagó participated in the 26th Argentine Congress of Hematology 2023, which was held from November 1st to the 4th at its two venues: the Sheraton Hotel and the Costa Galana Hotel, in the City of Mar del Plata.

Read note

New Product Launch VETRANO®palbociclib

We are thrilled to present to our community the launch of the product VETRANO® palbociclib, for our Oncology Line.

Read note